Product information and disease description
Place of product in therapy
165 evidence topics · 52 sources
Tovecimig (CTX-009)
Second-line advanced biliary tract cancer
- Manufacturer
- Compass Therapeutics
- Regulatory submission
- BLA planned for the fourth quarter of 2026
- Launch
- Anticipated in 2027
- Last updated